Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

35.27 -0.06 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 325,170
Open 35.78
Bid (Size) 35.15 (1)
Ask (Size) 36.42 (1)
Prev. Close 35.33
Today's Range 35.17 - 35.78
52wk Range 31.40 - 47.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings for Genmab
Via Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio. 
Via InvestorPlace

Performance

YTD
-18.03%
-18.03%
1 Month
-10.00%
-10.00%
3 Month
-7.21%
-7.21%
6 Month
-6.59%
-6.59%
1 Year
+10.46%
+10.46%

More News

Read More
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Analyst Expectations for Genmab's Future
Via Benzinga
Analyst Expectations for Genmab's Future
Via Benzinga
12 Analysts Have This to Say About Genmab
Via Benzinga
Why Shares of Iovance Biotherapeutics Dropped Thursday
Via The Motley Fool
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
Via Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Via The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
Via Benzinga
Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone
From Seagen Inc.
Via Business Wire
Where Genmab Stands With Analysts
Via Benzinga
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
From Genmab A/S
Via Business Wire
The 3 Most Promising Biotech Stocks to Own Now
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
Via Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
Via The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
Via The Motley Fool
3 Biotech Stocks You Better Be Buying on Each and Every Dip
Via InvestorPlace
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
3 Biotech Stocks That AI is Loving in July
Via InvestorPlace
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
Via The Motley Fool
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
Via Benzinga
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab
Via Business Wire
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
From Genmab
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.